Your Health, We Care
Venetoclax, also known as Venetoclax or Venetola, is a novel oral small molecule drug targeting BCL-2, developed in collaboration between AbbVie Inc in the United States and Genentech, a subsidiary of Roche Group inSwitzerland.Venetoclax exerts therapeutic effects by inhibiting the expression of BCL-2 protein, inducing cancer cells to enter an apoptotic state.
Venetoclax is a drug used to treat leukemias, specifically chronic lymphocytic l···【more】
Release date：2024-08-09Recommended：139
Venetoclax is a BCL-2 inhibitor that selectively binds to BCL-2 protein and inhi···【more】
Release date：2024-08-09Recommended：147
Venetoclax is a drug used to treat chronic lymphocytic leukemia (CLL) and certai···【more】
Release date：2024-08-09Recommended：142
